The Role of Complement in Kidney Disease

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2023 Sep 21

PMID 37735215

Authors

Vojtech Petr

Joshua M Thurman

Affiliations

Soon will be listed here.

Abstract

The complement cascade comprises soluble and cell surface proteins and is an important arm of the innate immune system. Once activated, the complement system rapidly generates large quantities of protein fragments that are potent mediators of inflammatory, vasoactive and metabolic responses. Although complement is crucial to host defence and homeostasis, its inappropriate or uncontrolled activation can also drive tissue injury. For example, the complement system has been known for more than 50 years to be activated by glomerular immune complexes and to contribute to autoimmune kidney disease. Notably, the latest research shows that complement is also activated in kidney diseases that are not traditionally thought of as immune-mediated, including haemolytic-uraemic syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. Several complement-targeted drugs have been approved for the treatment of kidney disease, and additional anti-complement agents are being investigated in clinical trials. These drugs are categorically different from other immunosuppressive agents and target pathological processes that are not effectively inhibited by other classes of immunosuppressants. The development of these new drugs might therefore have considerable benefits in the treatment of kidney disease.

Citing Articles

Claudin-2 enhances human antibody-mediated complement-dependent cytotoxicity of porcine endothelial cells by modulating antibody binding and complement activation.

Li W, Yang F, Yang D, Song Z, Xu Z, Wu J Front Immunol. 2025; 16:1547512.

PMID: 40040710 PMC: 11876394. DOI: 10.3389/fimmu.2025.1547512.

Nearing the Finish Line: Steady Progress in the Development of Complement Inhibitors for Glomerular Disease.

Thurman J Kidney Int Rep. 2025; 10(2):302-305.

PMID: 39990875 PMC: 11843313. DOI: 10.1016/j.ekir.2024.11.1370.

Glucosyl Hesperidin Supplementation Prevents Tubulointerstitial Fibrosis and Immune Activation in Diabetic Nephropathy in Mice.

Hashimoto K, Yoshida Y, Kamesawa M, Yazawa N, Tominaga H, Aisyah R Nutrients. 2025; 17(3).

PMID: 39940240 PMC: 11820413. DOI: 10.3390/nu17030383.

Kidney immunology from pathophysiology to clinical translation.

Kurts C, von Vietinghoff S, Krebs C, Panzer U Nat Rev Immunol. 2025; .

PMID: 39885266 DOI: 10.1038/s41577-025-01131-y.

Identifying Key Biomarkers Related to Immune Response in the Progression of Diabetic Kidney Disease: Mendelian Randomization Combined With Comprehensive Transcriptomics and Single-Cell Sequencing Analysis.

Hu M, Deng Y, Bai Y, Zhang J, Shen X, Shen L J Inflamm Res. 2025; 18:949-972.

PMID: 39871959 PMC: 11769850. DOI: 10.2147/JIR.S482047.

References

Thurman J, Lucia M, Ljubanovic D, Holers V . Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int. 2005; 67(2):524-30. DOI: 10.1111/j.1523-1755.2005.67109.x. View

Noris M, Ruggenenti P, Perna A, Orisio S, Caprioli J, Skerka C . Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic.... J Am Soc Nephrol. 1999; 10(2):281-93. DOI: 10.1681/ASN.V102281. View

Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M . The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020; 20(9):2318-2331. PMC: 7496245. DOI: 10.1111/ajt.15898. View

Reis E, Mastellos D, Hajishengallis G, Lambris J . New insights into the immune functions of complement. Nat Rev Immunol. 2019; 19(8):503-516. PMC: 6667284. DOI: 10.1038/s41577-019-0168-x. View

Stephan A, Barres B, Stevens B . The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012; 35:369-89. DOI: 10.1146/annurev-neuro-061010-113810. View

Arbore G, West E, Spolski R, Robertson A, Klos A, Rheinheimer C . T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4⁺ T cells. Science. 2016; 352(6292):aad1210. PMC: 5015487. DOI: 10.1126/science.aad1210. View

Zhang X, Kimura Y, Fang C, Zhou L, Sfyroera G, Lambris J . Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood. 2007; 110(1):228-36. PMC: 1896115. DOI: 10.1182/blood-2006-12-063636. View

Huber-Lang M, Sarma J, Zetoune F, Rittirsch D, Neff T, McGuire S . Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006; 12(6):682-7. DOI: 10.1038/nm1419. View

Holers V . Contributions of animal models to mechanistic understandings of antibody-dependent disease and roles of the amplification loop. Immunol Rev. 2022; 313(1):181-193. DOI: 10.1111/imr.13136. View

10.

Pouw R, Vredevoogd D, Kuijpers T, Wouters D . Of mice and men: The factor H protein family and complement regulation. Mol Immunol. 2015; 67(1):12-20. DOI: 10.1016/j.molimm.2015.03.011. View

11.

Ebanks R, Isenman D . Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol Immunol. 1996; 33(3):297-309. DOI: 10.1016/0161-5890(95)00135-2. View

12.

Brooimans R, Stegmann A, van Dorp W, van der Ark A, van der Woude F, van Es L . Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. J Clin Invest. 1991; 88(2):379-84. PMC: 295341. DOI: 10.1172/JCI115314. View

13.

Welch T, Beischel L, Frenzke M, Witte D . Regulated expression of complement factor B in the human kidney. Kidney Int. 1996; 50(2):521-5. DOI: 10.1038/ki.1996.344. View

14.

Zwirner J, FELBER E, Herzog V, Riethmuller G, Feucht H . Classical pathway of complement activation in normal and diseased human glomeruli. Kidney Int. 1989; 36(6):1069-77. DOI: 10.1038/ki.1989.302. View

15.

Dodds A, Matsushita M . The phylogeny of the complement system and the origins of the classical pathway. Immunobiology. 2007; 212(4-5):233-43. DOI: 10.1016/j.imbio.2006.11.009. View

16.

Matsushita M, Matsushita A, Endo Y, Nakata M, Kojima N, Mizuochi T . Origin of the classical complement pathway: Lamprey orthologue of mammalian C1q acts as a lectin. Proc Natl Acad Sci U S A. 2004; 101(27):10127-31. PMC: 454176. DOI: 10.1073/pnas.0402180101. View

17.

Garred P, Genster N, Pilely K, Bayarri-Olmos R, Rosbjerg A, Ma Y . A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev. 2016; 274(1):74-97. DOI: 10.1111/imr.12468. View

18.

Roos A, Rastaldi M, Calvaresi N, Oortwijn B, Schlagwein N, van Gijlswijk-Janssen D . Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006; 17(6):1724-34. DOI: 10.1681/ASN.2005090923. View

19.

Seifert L, Zahner G, Meyer-Schwesinger C, Hickstein N, Dehde S, Wulf S . The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nat Commun. 2023; 14(1):473. PMC: 9884226. DOI: 10.1038/s41467-023-36068-0. View

20.

HARBOE M, Ulvund G, Vien L, Fung M, Mollnes T . The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004; 138(3):439-46. PMC: 1809239. DOI: 10.1111/j.1365-2249.2004.02627.x. View